To investigate the molecular mechanisms through which LINC01432 may induce a short PFS to standard MM therapy and to test its potential as a therapeutic target, we used CRISPR/Cas9 (CRISPR) to knockdown LINC01432 expression in RPMI 8226 cells, Figure 3a, that have high endogenous expression levels, Supplementary Figure 3b. This evidence concerns the gene LINC01432 and Miyoshi myopathy.